Featured

Exhausted, yet effective: Eomes drives Th-mediated antitumor responses

While accumulating evidence suggests an important role for CD4+ T cells in antitumor immunity, the specific subpopulations responsible remain to be defined. Agesta, Ferrand, et al. investigated the function of the transcription factor Eomes in CD4+...

Case of complete response to immunotherapy in MMR-deficient prostate cancer associated with NK-like and CD4+CD8+ T cells

In a patient with advanced prostate cancer, pembrolizumab resulted in CR and, followed by a radical prostatectomy, prevented recurrence out to 18mo. Tumor whole-exome NGS indicated dMMR/MSI-H and an e...

A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling

Rodriguez and Edinger et al. showed that pre-treatment with VLA-4-targeted, low-dose radiopharmaceutical therapy (RPT) using [67Cu] Cu-LLP2A enhanced GD2 or B7-H3 CAR T cell efficacy, resulting in sig...

Activation of tumor-specific CD8+ T cells prior to radiopharmaceutical therapy improves antitumor response

Shim et al. investigated how the timing of tumor antigen-specific CD8+ T cell activation shaped responses to radiopharmaceutical therapy with ⁹⁰Y-NM600 (RPT) in E.G7-OVA and TRAMP-C1 tumor models. Low...

Tumor suppressor genotype influences the extent and mode of immunosurveillance in lung cancer

Using genetically engineered conditional mouse models and lentiviral-mediated somatic gene inactivation, Adler and Xu et al. developed models that allowed them to quantify immunoediting by evaluating ...

See all for this week

Previous Digests

Neutrophils not so neutral in tumors after all

June 24, 2026

Neutrophils in tumors are known to play both pro- and anti-inflammatory roles, but how they affect responses to immunotherapy is incompletely understood. In work recently published in Immunity, Pei et al. evaluated neutrophils in the context of several cancer...

taNKs on the frontline: CD39+ NK cells in the antitumor response

June 17, 2026

NK cell antitumor therapies are under development, but the functional states of tumoral NK cells remain poorly understood, limiting progress. Serger et al. profiled NK cells from non-small cell lung cancer (NSCLC) samples, identifying targetable subsets for immunotherapy. Their...

Unraveling the role of CCR1 in tumor myeloid cells

June 10, 2026

Pancreatic cancer (PDA) is a highly resistant and difficult-to-treat tumor type, often marked by extensive fibroinflammatory stroma and infiltration of immunosuppressive myeloid cells. These myeloid cells, including macrophages and granulocytes, have been noted to have high expression of CCR1...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ute Burkhardt

Ed Fritsch

Lauren Hitchings

Gaëlle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

— Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials